Jay S Skyler

Summary

Publications

  1. pmc Immunotherapy trials for type 1 diabetes: the contribution of George Eisenbarth
    Jay S Skyler
    Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, Florida 33136, USA
    Diabetes Technol Ther 15:S2-13-S2-20. 2013
  2. pmc Glucose excursions between states of glycemia with progression to type 1 diabetes in the diabetes prevention trial-type 1 (DPT-1)
    Jay M Sosenko
    Division of Endocrinology, University of Miami, Miami, Florida, USA
    Diabetes 59:2386-9. 2010
  3. ncbi A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1
    Jay M Sosenko
    Division of Endocrinology, University of Miami, P O Box 016960 D110, Miami, FL 33101, USA
    Diabetes Care 31:528-33. 2008
  4. ncbi Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial-Type 1
    Jay M Sosenko
    Division of Endocrinology, University of Miami, P O Box 016960 D110, Miami, FL 33101, USA
    Diabetes Care 30:38-42. 2007
  5. pmc The application of the diabetes prevention trial-type 1 risk score for identifying a preclinical state of type 1 diabetes
    Jay M Sosenko
    Division of Endocrinology, University of Miami, Miami, FL, USA
    Diabetes Care 35:1552-5. 2012
  6. pmc Trends of earlier and later responses of C-peptide to oral glucose challenges with progression to type 1 diabetes in diabetes prevention trial-type 1 participants
    Jay M Sosenko
    Division of Endocrinology, University of Miami, Miami, Florida, USA
    Diabetes Care 33:620-5. 2010
  7. pmc A longitudinal study of GAD65 and ICA512 autoantibodies during the progression to type 1 diabetes in Diabetes Prevention Trial-Type 1 (DPT-1) participants
    Jay M Sosenko
    ivision of Endocrinology, University of Miami, Miami, Florida, USA
    Diabetes Care 34:2435-7. 2011
  8. pmc Incident dysglycemia and progression to type 1 diabetes among participants in the Diabetes Prevention Trial-Type 1
    Jay M Sosenko
    Division of Endocrinology, University of Miami, Miami, Florida, USA
    Diabetes Care 32:1603-7. 2009
  9. pmc Glucose and C-peptide changes in the perionset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1
    Jay M Sosenko
    Division of Endocrinology, University of Miami, Miami, Florida, USA
    Diabetes Care 31:2188-92. 2008
  10. pmc The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients
    Jay M Sosenko
    Division of Endocrinology, University of Miami, Miami, Florida, USA
    Diabetes Care 36:2615-20. 2013

Collaborators

Detail Information

Publications25

  1. pmc Immunotherapy trials for type 1 diabetes: the contribution of George Eisenbarth
    Jay S Skyler
    Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, Florida 33136, USA
    Diabetes Technol Ther 15:S2-13-S2-20. 2013
    ..Thus, we believe his greatest contribution is yet to come, as in the near future we should see this most recent work translate into clinical trials...
  2. pmc Glucose excursions between states of glycemia with progression to type 1 diabetes in the diabetes prevention trial-type 1 (DPT-1)
    Jay M Sosenko
    Division of Endocrinology, University of Miami, Miami, Florida, USA
    Diabetes 59:2386-9. 2010
    ..We characterized fluctuations between states of glycemia in progressors to type 1 diabetes and studied whether those fluctuations are related to the early C-peptide response to oral glucose...
  3. ncbi A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1
    Jay M Sosenko
    Division of Endocrinology, University of Miami, P O Box 016960 D110, Miami, FL 33101, USA
    Diabetes Care 31:528-33. 2008
    ..The accurate prediction of type 1 diabetes is essential for appropriately identifying prevention trial participants. Thus, we have developed a risk score for the prediction of type 1 diabetes...
  4. ncbi Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial-Type 1
    Jay M Sosenko
    Division of Endocrinology, University of Miami, P O Box 016960 D110, Miami, FL 33101, USA
    Diabetes Care 30:38-42. 2007
    ....
  5. pmc The application of the diabetes prevention trial-type 1 risk score for identifying a preclinical state of type 1 diabetes
    Jay M Sosenko
    Division of Endocrinology, University of Miami, Miami, FL, USA
    Diabetes Care 35:1552-5. 2012
    ..We assessed the utility of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for identifying individuals who are highly likely to progress to type 1 diabetes (T1D) within 2 years...
  6. pmc Trends of earlier and later responses of C-peptide to oral glucose challenges with progression to type 1 diabetes in diabetes prevention trial-type 1 participants
    Jay M Sosenko
    Division of Endocrinology, University of Miami, Miami, Florida, USA
    Diabetes Care 33:620-5. 2010
    ..001); peak C-peptide levels were less predictive (P < 0.05). CONCLUSIONS A decreased early C-peptide response to oral glucose and an increased later response occur at least 2 years before the diagnosis of type 1 diabetes...
  7. pmc A longitudinal study of GAD65 and ICA512 autoantibodies during the progression to type 1 diabetes in Diabetes Prevention Trial-Type 1 (DPT-1) participants
    Jay M Sosenko
    ivision of Endocrinology, University of Miami, Miami, Florida, USA
    Diabetes Care 34:2435-7. 2011
    ..We examined changes in GAD65 and ICA-512 autoantibodies (GADA and IA-2A) during progression to type 1 diabetes (T1D)...
  8. pmc Incident dysglycemia and progression to type 1 diabetes among participants in the Diabetes Prevention Trial-Type 1
    Jay M Sosenko
    Division of Endocrinology, University of Miami, Miami, Florida, USA
    Diabetes Care 32:1603-7. 2009
    ..We studied the incidence of dysglycemia and its prediction of the development of type 1 diabetes in islet cell autoantibody (ICA)-positive individuals. In addition, we assessed whether dysglycemia was sustained...
  9. pmc Glucose and C-peptide changes in the perionset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1
    Jay M Sosenko
    Division of Endocrinology, University of Miami, Miami, Florida, USA
    Diabetes Care 31:2188-92. 2008
    ..We examined metabolic changes in the period immediately after the diagnosis of type 1 diabetes and in the period leading up to its diagnosis in Diabetes Prevention Trial-Type 1 (DPT-1) participants...
  10. pmc The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients
    Jay M Sosenko
    Division of Endocrinology, University of Miami, Miami, Florida, USA
    Diabetes Care 36:2615-20. 2013
    ..We assessed whether a risk score that incorporates levels of multiple islet autoantibodies could enhance the prediction of type 1 diabetes (T1D)...
  11. pmc A comparison of the baseline metabolic profiles between Diabetes Prevention Trial-Type 1 and TrialNet Natural History Study participants
    Jay M Sosenko
    Division of Endocrinology, University of Miami, Miami, FL, USA
    Pediatr Diabetes 12:85-90. 2011
    ..We assessed whether differing autoantibody screening criteria for type 1 diabetes (T1D) prevention trials result in different baseline metabolic profiles of those who screen positive...
  12. pmc Validation of the Diabetes Prevention Trial-Type 1 Risk Score in the TrialNet Natural History Study
    Jay M Sosenko
    University of Miami, Miami, FL, USA
    Diabetes Care 34:1785-7. 2011
    ..We assessed the accuracy of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS), developed from the Diabetes Prevention Trial-Type 1 (DPT-1), in the TrialNet Natural History Study (TNNHS)...
  13. pmc Type 1 Diabetes TrialNet--an international collaborative clinical trials network
    Jay S Skyler
    Diabetes Research Institute, Miami, Florida 33101 6960, USA
    Ann N Y Acad Sci 1150:14-24. 2008
    ....
  14. ncbi Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1
    Jay M Sosenko
    Division of Endocrinology, University of Miami, PO Box 016960 D110, Miami, FL 33101, USA
    Diabetes Care 29:643-9. 2006
    ..The goal of this study was to utilize data from the Diabetes Prevention Trial-Type 1 (DPT-1) to obtain a picture of the metabolic progression to type 1 diabetes over a period of approximately 2.5 years before its diagnosis...
  15. ncbi Pulmonary insulin update
    Jay S Skyler
    University of Miami, Miami, Florida 33136, USA
    Diabetes Technol Ther 7:834-9. 2005
  16. ncbi Two-year safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 1 diabetes
    Jay S Skyler
    Division of Endocrinology, Diabetes, and Metabolism, University of Miami, Miami, FL 33136, USA
    Diabetes Care 30:579-85. 2007
    ..The purpose of this study was to evaluate the long-term (2-year) safety and efficacy of inhaled human insulin (Exubera [insulin human (rDNA origin)] inhalation powder) (EXU) in adult patients with type 1 diabetes...
  17. ncbi Pulmonary insulin delivery--state of the art 2007
    Jay S Skyler
    Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, Florida 33136, USA
    Diabetes Technol Ther 9:S1-3. 2007
  18. doi Central obesity and insulin resistance in the cardiometabolic syndrome: pathways to preclinical cardiovascular structure and function
    Johanna R Klaus
    Behavioral Medicine Research Center, University of Miami, Miami, FL 33136, USA
    J Cardiometab Syndr 4:63-71. 2009
    ..The findings suggest predominant pathways through which subclinical metabolic processes may exert pathogenic impact on the heart and vasculature...
  19. ncbi Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial
    Jay S Skyler
    University of Miami, School of Medicine, Miami, FL 33136, USA
    Diabetes Care 28:1630-5. 2005
    ..We investigated whether a basal/bolus insulin regimen involving rapid-acting, dry powder, inhaled insulin could provide glycemic control comparable with a basal/bolus subcutaneous regimen...
  20. pmc Immune profiling by multiple gene expression analysis in patients at-risk and with type 1 diabetes
    Dongmei Han
    Diabetes Research Institute, Leonard Miller School of Medicine, University of Miami, FL 33136, USA
    Clin Immunol 139:290-301. 2011
    ..Data suggest an overall depressed immunity in long-term type 1 DM. Increased gene expression levels for IFN-γ, IL-4 and IL-10 in new-onset patients from at-risk patients might be used as potential markers for progression of the disease...
  21. ncbi Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1
    Jay S Skyler
    University of Miami, PO Box 016960 D 110, Miami, FL 33101 6960, USA
    Diabetes Care 28:1068-76. 2005
    ..This randomized, double-masked, placebo-controlled clinical trial tested whether oral insulin administration could delay or prevent type 1 diabetes in nondiabetic relatives at risk for diabetes...
  22. doi Decision-making in diabetes mellitus type 1
    James K Rustad
    Dept of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, FL, USA
    J Neuropsychiatry Clin Neurosci 25:40-50. 2013
    ..Future studies utilizing novel treatment strategies to help patients with type 1 DM make better decisions about their disease may improve their glycemic control and quality of life, while minimizing the impact of end-organ disease...
  23. ncbi Diabetes mellitus: pathogenesis and treatment strategies
    Jay S Skyler
    Division of Endocrinology, Diabetes, and Metabolism, University of Miami D 110, 1450 NW 10th Avenue, Suite 3061, Miami, Florida 33136, USA jskyler miami edu
    J Med Chem 47:4113-7. 2004
    ..This article introduces the disease state of diabetes mellitus and provides a background of the impact of the disease on the population, its biology and pathophysiology, and the current treatment strategies for treating diabetes...
  24. pmc Update on worldwide efforts to prevent type 1 diabetes
    Jay S Skyler
    Diabetes Research Institute, Miami, Florida 33101 6960, USA
    Ann N Y Acad Sci 1150:190-6. 2008
    ..These have tested nicotinamide, parenteral insulin, oral insulin, nasal insulin, and the elimination of cow's milk from infant feeding...
  25. doi An analysis of characteristics of subjects examined for incretin effects on pancreatic pathology
    Evis Harja
    Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA
    Diabetes Technol Ther 15:609-18. 2013
    ....